UNSPSC 51314317: Belladonna/chlorpheniramine/pheniramine/phenylpropanolamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.

UNSPSC 51314317 Belladonna/chlorpheniramine/pheniramine/phenylpropanolamine is a Commodity code that in recent state and local procurement reflects broader pharmaceutical and over-the-counter product procurement rather than the specific antihistamine and decongestant compounds its name denotes. State and local governments soliciting under this code are acquiring pharmaceutical products, naloxone, drug deactivation systems, and generic multi-source medications through competitive bidding and cooperative purchasing frameworks. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and cooperative purchasing alliances serving multiple states and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, which includes Oregon). The procurement activity spans both direct product supply through IFBs and RFPs, as well as preliminary market-intelligence gathering through RFIs to shape future contracting strategies for pharmacy benefit programs and direct-to-manufacturer prescription initiatives.

Recent opportunities demonstrate geographic spread across Florida, Texas, and Minnesota with multistate reach through MMCAP. Seminole County, Florida posted an IFB (IFB60459723LAS) on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023, through electronic bidding with fixed-fee pricing and a two-year term plus one-year renewal option. The Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026, to gather vendor capabilities on implementing a Therapeutic Pharmacy Initiative for direct-to-manufacturer prescriptions without traditional pharmacy benefit managers or group purchasing organizations. The Minnesota Department of Administration's Office of State Procurement administered an MMCAP RFP (S1070000015802) posted January 20, 2026, with proposals due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, requiring NDC compliance, cGMP and DSCSA certification, and a two-year initial contract term with optional extensions.